For two years, compounded semaglutide was the easiest margin in aesthetics. That era is over, and a lot of clinics are still running the old math on a service line that no longer works the way it did. Here is what changed, and where the profit actually lives now.
By Jhonny Garcia · Founder, Opulent Marketing Strategies · Jacksonville, FL
Compounded GLP-1s were legal at scale because of a drug shortage. When a drug is on the FDA shortage list, compounding pharmacies may produce versions of it. The FDA resolved the tirzepatide shortage in late 2024 and the semaglutide shortage in February 2025, and with those designations gone the legal basis for routine compounded copies went with them.
The general rule underneath is simple: a pharmacy may not compound something that is essentially a copy of a commercially available approved drug. Narrow exceptions exist for clinically significant modifications for a specific patient — that is a genuine clinical pathway, not a volume business model, and treating it as a workaround is how clinics end up in enforcement letters.
The practical result: the $200-a-month vial that supported a $500-a-month program is largely gone, and it is not coming back on the old terms.
Under compounding, the economics were unusually forgiving. Drug cost was low, the markup carried the program, and the clinical service around it was almost incidental to profitability.
Under branded product, acquisition cost rises sharply and — this is the part clinics underestimate — the manufacturers now sell directly to patients. Both Lilly and Novo run direct cash-pay channels at prices a med spa cannot beat on the molecule alone. If your program's value proposition is "we sell you the drug," you are now competing on price against the company that makes it.
That is the real shift. Not that weight-loss stopped being profitable, but that drug markup stopped being the profit center.
It moved to everything around the injection, and this is genuinely good news for a med spa — because a clinic can deliver those things and a mail-order pharmacy cannot.
The wraparound is the product now: baseline labs and interpretation, body composition tracking rather than scale weight, dose titration managed by a clinician, side-effect management in the first eight weeks when most drop-off happens, nutrition and protein guidance to protect lean mass, and an actual human who answers when a patient feels awful on week three. Priced as a monthly clinical program rather than a drug transaction, that supports real margin and it is defensible against DTC pricing.
Retention is the second half. GLP-1 patients are monthly by nature — the highest-frequency relationship in aesthetics. A patient who stays twelve months is worth several times one who churns at month three, and early side-effect support is the single biggest determinant of which one you get.
Rapid weight loss changes faces. Volume loss in the midface, laxity, and hollowing — the phenomenon patients themselves call Ozempic face — arrives for a meaningful share of successful GLP-1 patients, usually somewhere between months four and nine.
For a med spa this is the most natural cross-sell that exists. The patient is already in your chair monthly, already trusts you, and is experiencing a cosmetic concern you already treat: filler for volume restoration, skin tightening, biostimulators. A weight-loss program with no aesthetic pathway attached is leaving the most valuable half of the patient's lifetime value on the table.
Run properly, the weight-loss line is not really a weight-loss business. It is the highest-frequency patient acquisition channel your aesthetic practice has ever had.
Advertising claims are where the enforcement risk concentrates. Avoid promising specific pounds or timelines, avoid presenting compounded product as equivalent to branded, avoid brand names in ways that imply affiliation, and be careful with before-and-after imagery in paid placements — the same rules that apply to injectables apply here.
The safest and most effective positioning is the program, not the drug: describe the clinical oversight, the monitoring, the support. It is compliant, it is differentiated from every telehealth competitor, and it happens to be the thing you actually sell.
Yes, for most clinics — but as a clinical program with an aesthetic pathway attached, not as a pharmacy with a lobby. Practices offering medical weight-loss have consistently outperformed those that do not, and the patient frequency is unmatched.
The clinics that struggle in 2026 are the ones still selling the molecule. The ones that thrive rebuilt the offer around the service, priced it monthly, defended retention through the rough early weeks, and treated every weight-loss patient as a future aesthetic patient.
Yes, but the profit moved. Drug markup no longer carries the program now that compounding is largely closed and manufacturers sell directly to patients. Profitable programs are priced as monthly clinical services — labs, titration, side-effect management, body composition — with an aesthetic cross-sell attached.
Not as a routine volume model. With the shortage designations resolved, compounding what is essentially a copy of an available approved drug is generally prohibited. Narrow clinical exceptions exist for patient-specific modifications, but they are not a business model.
Volume restoration and skin tightening. Rapid weight loss commonly produces midface volume loss and laxity between months four and nine — a cosmetic concern your clinic already treats, in a patient who is already visiting monthly.
We fill one med spa's calendar per city with 30+ qualified consults a month — guaranteed in 90 days or we work free. Start with the free guide, or apply to see if your city's open.